Article | October 9, 2023

Risk Mitigation For Late-Stage Clinical Assets

By Amy Trotch, Business Development Director/Commercial Technical Transfer, Societal CDMO


Post-pandemic, there is an increasing demand for the CDMO-Biopharma relationship to focus on, dare we say it, “strategic partnering.” Strategic partnering – that industry buzz term used so loosely, with such frequency and abundance, that it edges close to a cliché. Yet, while it is true that the term is often overused and loosely defined when it’s precisely broken down, its basic definition holds the truest of post-pandemic lessons learned.

In today’s unpredictable and challenging times, leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering. The value-add of a CDMO functioning on this level of partnership, as a trusted and experienced advisor that can provide flexible solutions for late-stage risk mitigation stretches far beyond what is expected in the manufacturing suite.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online